Nuwellis (NUWE) investor relations material

Investment highlights

• Aquadex ultrafiltration technology offers precise, predictable fluid removal, reducing readmissions and improving outcomes.

• Platform expansion targets new indications and leverages partnerships to broaden cardiorenal solutions.

• Addressable U.S. market opportunity exceeds $4.2 billion across five clinical segments.

• Pediatric segment represents 50% of revenues, with adoption in leading children's hospitals.

• 1H26 revenue grew 20% year-over-year, with gross margins improving to 76%.

Clinical need and solution

• Fluid overload is a major driver of mortality and hospital readmissions in critical care, heart failure, and pediatrics.

• Aquadex provides low-volume ultrafiltration for controlled fluid removal when diuretics fail.

• System is adopted in ICU, cardiac surgery, and pediatric critical care programs.

• Technology enables precise, gentle fluid management, especially for low-weight pediatric patients.

Business model and commercial execution

• Aquadex system generates high-margin recurring revenue through single-use disposables.

• Flexible acquisition models include purchase, lease, or rental of capital equipment.

• Broad clinical coverage with 29% pediatric, 28% critical care, and 27% heart failure segment growth in H1.

• Active in ~135 hospital accounts, including top academic centers.